Psyence Group Inc.

Equities

PSYG

CA74449Q1063

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 03:43:26 2024-04-22 pm EDT			5-day change	1st Jan Change
0.03 ^CAD	+20.00%		0.00%	-40.00%

Mar. 26	Psyence Group Closes Strategic Restructuring of Its Non-Clinical Business	MT
Mar. 26	An undisclosed buyer completed the acquisition of Mind Health Ltd and Psyence Uk Group Ltd from Psyence Group Inc..	CI

Psyence Group Inc. announced that it has received CAD 0.933116 million in funding from Cantheon Capital

March 22, 2023

On March 23, 2023, Psyence Group Inc. closed the transaction. The company has issued 7,775,964 common shares at a price of CAD 0.12 per common share and 3,887,982 warrants for the gross proceeds of CAD 933,116 in the transaction.

Latest news about Psyence Group Inc.

Psyence Group Closes Strategic Restructuring of Its Non-Clinical Business	Mar. 26	MT
An undisclosed buyer completed the acquisition of Mind Health Ltd and Psyence Uk Group Ltd from Psyence Group Inc..	Mar. 25	CI
Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division	Mar. 11	MT
Psyence Group Inc. Announces Resignation of Neil Maresky as CEO	Mar. 11	CI
Psyence Group Inc. Announces CFO Changes	Mar. 11	CI
Psyence Group Inc. Announces Board Resignations	Mar. 11	CI
An undisclosed buyer entered into a conditional agreement to acquire Mind Health Ltd and Psyence Uk Group Ltd from Psyence Group Inc. for CAD 1 million.	Mar. 10	CI
Psyence Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 28	CI
Psyence Biomedical Approved to List on Nasdaq Following Completion of Business Combination With Newcourt Acquisition Corp	Jan. 26	MT
Psyence Group Inc. Announces Resignation of Marvin Singer as Board Member	Nov. 20	CI
Psyence Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Psyence Group Inc. Designs New Laboratory at Facility in Order to Expand its Extraction Capabilities	23-10-30	CI
Psyence Group Inc. announced that it has received CAD 0.162697 million in funding	23-10-29	CI
Psyence Group Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Psyence Group Inc. announced that it has received CAD 0.126773 million in funding	23-08-20	CI
Psyence Group Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-27	CI
Psyence Group Inc. Appoints Christopher Bull to Board of Directors	23-07-11	CI
Psyence Group Inc. announced that it has received CAD 4.262204 million in funding	23-03-30	CI
Psyence Group Inc. announced that it has received CAD 3.00854 million in funding	23-03-30	CI
Psyence Group Inc. announced that it has received CAD 0.933116 million in funding from Cantheon Capital	23-03-22	CI
Psyence Group Inc. announced that it expects to receive CAD 1.923375 million in funding	23-03-21	CI
Psyence Group Inc. Partners with iNGEN for Palliative Care Clinical Trial in Australia	23-03-21	CI
Psyence Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-03-01	CI
Psyence Group and Eden Labs Announce Extraction and Product Development Collaboration	23-01-24	MT
Psyence Group Inc. and Eden Labs LLC Announces Extraction and Product Development Collaboration	23-01-24	CI

Chart Psyence Group Inc.

Duration

Period

More charts

Company Profile

Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Companyâs divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PSYENCE GROUP INC.	-40.00%	3.05M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research